Zhi Guo MD, PhD, Presenter: Nothing to Disclose

HaiTao Wang, Abstract Co-Author: Nothing to Disclose

WenGe Xing, Abstract Co-Author: Nothing to Disclose

Fang Liu, Abstract Co-Author: Nothing to Disclose

BaoGuo Li, Abstract Co-Author: Nothing to Disclose

Tong Guo Si MD, Abstract Co-Author: Nothing to Disclose

Haipeng Yu MD, Abstract Co-Author: Nothing to Disclose

Ni Hong MD, Abstract Co-Author: Nothing to Disclose

Zou Qiang MD, Abstract Co-Author: Nothing to Disclose

We prospectively assessed the effectiveness of selective transcatheter arterial chemoembolization for the palliative treatment of hormone-refractory prostate cancer.

Eighteen patients, median age 69 years (range 51-92) with histologically confirmed prostate cancer, were enrolled into a prospective clinical trial to evaluate the possible toxic and beneficial effects of selective transcatheter arterial chemoembolization(TACE). they had stage C or D tumor progression and complained of difficult urination or bone pain caused by intrapelvic tumor infiltration. Hormone therapy had been done before the selective TACE therapy but the clinical status showed little change with a persistence of local symptoms. All patients received TACE treatment using MTX, ADM, and CDDP mixed with iodized oil as one course and was repeated for three courses at 4-week intervals. Hormonal therapy was continued throughout the trial to avoid the known withdrawal effect of anti-androgen on PSA levels. Assessment of PSA level, primary tumor response with CT and endorectal MR and MR spectroscopic imaging, metastasic tumor response with bone scintigraphy, quality of life using FACT-P and IPSS questionnaires and toxicity were completed for each patient before and after 4, 8, 12, 16 and 20 weeks of TACE treatment.

Angiography and CT performed after chemoembolization showed intensive iodinal oil deposition in the prostate gland. The chemoembolization was associated with significant improvements in quality-of-life measures(P<0.05) and a decline in PSA levels (P<0.01), with no major side-effects. As judged from the response of prostate-specific antigen (PSA), a complete response (CR) was obtained in 10 cases, a PR, in 5 cases; and NC and progressive disease (PD), in 3 cases each.

These results support selective transcatheter arterial chemoembolization is a safe and effective technique for patients with hormone-refractory prostate cancer and can improve patients’ quality of life by improving voiding symptoms associated with this malignancy and reducing PSA levels,prostate volume.

chemoembolization is a safe and effective for hormone-refractory prostate cancer and improve quality of life

Guo, Z, Wang, H, Xing, W, Liu, F, Li, B, Si, T, Yu, H, Hong, N, Qiang, Z, Selective Transcatheter Arterial Chemoembolization for the Palliative Treatment of Hormone-Refractory Prostate Cancer.  Radiological Society of North America 2007 Scientific Assembly and Annual Meeting, November 25 - November 30, 2007 ,Chicago IL. http://archive.rsna.org/2007/5014265.html